내시경 체중 감량 치료 시장은 2025년에 3억 1,758만 달러로 평가되었습니다. 2026년에는 3억 5,803만 달러에 이르고, CAGR 10.79%로 성장을 지속하여 2032년까지 6억 5,074만 달러에 달할 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도 : 2025년 | 3억 1,758만 달러 |
| 추정 연도 : 2026년 | 3억 5,803만 달러 |
| 예측 연도 : 2032년 | 6억 5,074만 달러 |
| CAGR(%) | 10.79% |
체중 감량에 대한 내시경적 접근은 실험적 기술에서 소화기내과, 비만외과, 외래 수술이 교차하는 체계적인 임상 경로로 성숙했습니다. 새로운 기술들은 비만을 최소침습적 내시경적 개입이 가능한 질환으로 간주하고, 순수하게 외과적 해결책에서 합병증 위험 감소, 빠른 회복, 임상적으로 적절한 경우 반복성을 중시하는 시술로 치료 방향을 전환하고 있습니다. 이러한 진화로 인해 의료기기 제조업체, 보험사, 다직종 진료팀을 포함한 다양한 이해관계자들이 임상 알고리즘과 환자 선택 기준을 재평가해야 하는 상황에 직면해 있습니다.
내시경 체중 감량 치료 분야는 기기 플랫폼의 혁신, 임상 진료 패턴의 진화, 그리고 강화된 다학제적 협력으로 인해 혁신적인 변화를 경험하고 있습니다. 제조업체들은 봉합, 스테이플링, 흡입, 위내 시스템 등에서 반복적인 개선을 통해 안전성을 높이고 사용자 인터페이스를 단순화하여 보다 광범위한 채택을 촉진하고 있습니다. 그 결과, 술기 습득 기간이 단축되고, 외래 진료 및 외래 수술센터 환경으로의 보급이 촉진되어 전문 3차 의료기관을 넘어 다양한 임상의의 참여를 지원하고 있습니다.
2025년을 향한 미국의 관세 조치와 무역 정책 조정은 세계 의료기기 공급망에 의존하는 공급업체와 의료 서비스 제공업체에게 새로운 업무상의 복잡성을 야기하고 있습니다. 특정 수입 부품에 대한 관세 인상은 내시경 시스템의 비용 구조에 영향을 미칠 수 있으며, 특히 특수 공구 및 정밀 소모품이 국제적인 제조 기지에서 조달되는 경우 특히 그렇습니다. 이에 따라 의료 제공업체와 조달팀은 공급업체 계약 재평가, 장기 계약 협상, 단가 이상의 총 착륙 비용에 대한 영향 검토 등 더 많은 압력에 직면하고 있습니다.
치료법 유형에 따른 시장 세분화는 흡입 요법, 내시경적 슬리브 위 성형술, 위내 풍선 요법에서 각각 다른 임상적 역할과 기술적 요구 사항을 강조합니다. AspireAssist 플랫폼과 같은 시스템으로 대표되는 흡입 요법은 내구성 있는 배액 인터페이스와 환자 스스로의 관리 프로토콜을 중요시하며, 시술자에 의한 시술과는 다른 교육과 후속 조치가 필요합니다. 내시경 슬리브 위 성형술은 스테이플 링 시스템과 봉합 시스템으로 분류되며, 각각 다른 장치 조작성, 장비 투자 요구 사항, 임상 숙달 곡선을 가져와 소화기 전문의와 비만 치료 팀의 채용 결정에 영향을 미칩니다. 위내 풍선은 다시 장기용과 단기용으로 나뉘는데, 장기용 장치는 지속적 삽입과 회수 가능한 디자인을 중시하는 반면, 단기용 풍선은 시술의 복잡성을 줄인 일시적 용량 대체에 초점을 맞추었습니다.
내시경적 체중감량 요법의 도입, 급여화, 의료 시스템 전반의 확대는 지역별로 큰 영향을 미칩니다. 미국 대륙에서는 이미 구축된 임상 네트워크와 상대적으로 높은 비만 유병률이 조기 도입의 기반이 되고 있으며, 비용 효율성이 높은 저침습적 치료법에 대한 지불자 측의 관심도 높아지고 있습니다. 이 지역의 의료 서비스 제공업체들은 외래환자 프로그램 시험 도입을 늘리고, 기기를 다직종 협력 체중 관리 프로세스에 통합하여 임상의의 숙련도 향상과 환자 의뢰의 흐름을 가속화하고 있습니다.
내시경 체중감량 요법을 지원하는 기업 환경은 경쟁과 협업의 역학에 의해 형성되고 있습니다. 주요 기기 개발 업체들은 시술의 안전성 향상, 사용자 인터페이스의 단순화, 연구자 주도 시험 및 레지스트리를 통한 증거 기반 확충에 주력하고 있습니다. 동시에, 장비 공급업체와 임상 네트워크 간의 전략적 제휴를 통해 교육 프로그램을 가속화하고, 조기 도입 시설에 대한 접근을 확대하며, 지불자와의 대화에 도움이 되는 실용적인 데이터 수집을 가능하게 했습니다. 인수합병은 주요 기업들이 차별화된 기술을 확보하고 소모품, 자본 장비, 디지털 환자 참여 도구에 걸친 종합적인 포트폴리오를 구축하기 위한 효과적인 수단으로 활용되고 있습니다.
업계 리더은 내시경 체중감량 치료의 책임감 있는 도입을 가속화하기 위해 임상적 근거 창출, 지불자와의 협력, 운영 전개 등을 통합하는 협력 전략을 채택해야 합니다. 첫째, 지속적인 환자 결과와 의료비 지표를 포착하는 전향적 리얼월드 연구와 다기관 레지스트리를 우선시해야 합니다. 확고한 결과 데이터는 상환 협상과 임상의의 신뢰를 실질적으로 강화합니다. 다음으로, 실습 시뮬레이션, 프록터링, 디지털 기술 향상을 결합한 확장 가능한 임상의 교육 프로그램에 투자하여, 다양한 진료 환경에서의 도입 곡선을 단축하고, 시술의 편차를 줄여야 합니다.
본 조사방법은 1차 정성조사와 체계적인 2차 조사를 결합하여 종합적이고 검증된 결론을 보장하기 위해 1차 정성조사와 체계적인 2차 조사를 병행합니다. 1차 조사에서는 임상의, 병원 조달 책임자, 외래 수술 관리자, 의료기기 제조업체 경영진을 대상으로 구조화된 인터뷰를 실시했으며, 다분야 전문가로 구성된 자문위원회에서 토론을 통해 보완했습니다. 이러한 노력을 통해 시술 워크플로우, 교육 요구, 상환 협상, 조달 판단 기준에 대한 배경 정보를 얻었습니다. 다양한 지역과 의료 제공업체 유형을 대상으로 인터뷰를 실시하여 다양한 운영 관점을 반영하였습니다.
결론적으로, 내시경 체중 감량 치료는 기술의 정교화, 근거의 성숙, 의료 제공 경제의 변화에 의해 형성되는 중요한 분기점에 서 있습니다. 기기 인체공학적 개선, 실용적 결과 연구, 확대된 교육 인프라의 누적 효과로 전문 3차 의료기관을 넘어 시술에 대한 접근성을 확대할 수 있는 가능성이 높아지고 있습니다. 그러나 일상적인 임상 통합으로 가는 길은 증거 창출, 지불자와의 협력, 공급망 회복력에서 협력적인 행동에 달려있습니다.
The Endoscopic Weight Loss Therapy Market was valued at USD 317.58 million in 2025 and is projected to grow to USD 358.03 million in 2026, with a CAGR of 10.79%, reaching USD 650.74 million by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 317.58 million |
| Estimated Year [2026] | USD 358.03 million |
| Forecast Year [2032] | USD 650.74 million |
| CAGR (%) | 10.79% |
Endoscopic approaches to weight loss have matured from experimental techniques into structured clinical pathways that intersect gastroenterology, bariatrics, and ambulatory surgery. Emerging technologies now treat obesity as a condition amenable to minimally invasive endoluminal interventions, shifting care away from purely surgical solutions toward procedures that emphasize lower morbidity, quicker recovery, and repeatability when clinically appropriate. This evolution has invited a broader set of stakeholders-including device manufacturers, payers, and multidisciplinary care teams-to reassess clinical algorithms and patient selection criteria.
Clinicians increasingly view endoscopic therapies as complementary to lifestyle and pharmacologic interventions rather than as standalone endpoints. Consequently, iterative improvements in device design, procedural workflows, and post-procedure support models have focused attention on long-term patient engagement and outcome tracking. At the same time, regulatory pathways and reimbursement conversations have adapted to accommodate the growing evidence base, which in turn influences capital allocation and adoption pacing across care settings.
As we examine the landscape further, it becomes clear that the convergence of clinical need, technological refinement, and shifting provider economics has created an inflection point. Strategic stakeholders must therefore align clinical evidence generation, payer engagement, and commercialization strategies to realize the full potential of endoscopic weight loss therapies within contemporary care delivery models.
The landscape of endoscopic weight loss therapy has experienced transformative shifts driven by innovation in device platforms, evolving clinical practice patterns, and strengthened interdisciplinary collaboration. Manufacturers have invested in iterative improvements across suturing, stapling, aspiration, and intragastric systems to enhance safety profiles while simplifying user interfaces for wider adoption. As a result, procedural learning curves have shortened, which facilitates diffusion into outpatient and ambulatory surgical settings and supports broader clinician participation beyond specialized tertiary centers.
Meanwhile, the integration of endoscopic therapies with structured weight management programs has shifted emphasis toward longitudinal care models. This movement encourages the deployment of digital health tools for patient engagement, remote monitoring, and outcomes assessment, thereby reinforcing the role of endoscopic therapies within comprehensive obesity management pathways. Additionally, regulatory clarity in several jurisdictions has allowed manufacturers and providers to pursue robust post-market evidence generation and pragmatic clinical studies that better reflect real-world practice.
Taken together, these shifts reduce barriers to clinical adoption and create new commercial pathways. Forward-looking stakeholders will therefore prioritize interoperability with care pathways, evidence-based reimbursement strategies, and partnerships that expand procedure accessibility across diverse clinical settings.
Recent tariff actions and trade policy adjustments within the United States for 2025 have introduced a new layer of operational complexity for suppliers and providers who rely on global medical device supply chains. Increased duties on select imported components can affect cost structures for endoscopic systems, particularly where specialized tooling and precision consumables are sourced from international manufacturing hubs. Accordingly, providers and procurement teams face heightened pressure to reassess supplier agreements, negotiate longer-term contracts, and examine total landed cost implications beyond unit price.
In response, manufacturers are exploring mitigation strategies that include supplier diversification, qualification of alternate component sources, and selective relocation of discrete manufacturing steps closer to major demand markets. These actions aim to insulate product availability and reduce exposure to tariff volatility. At the same time, some organizations will likely absorb incremental costs temporarily to maintain competitive pricing and market access, while others may implement measured price adjustments or revise service and consumable pricing models.
Importantly, increased tariffs intersect with reimbursement negotiations and capital purchasing cycles; providers must therefore anticipate procurement timing and evaluate the fiscal impact on capital acquisition decisions for new endoscopic platforms. In sum, trade policy changes in 2025 compel both vendors and healthcare purchasers to adopt more resilient sourcing strategies and proactive commercial planning to sustain supply continuity and predictable cost dynamics.
Segmentation of the market by therapy type highlights distinct clinical roles and technological demands across aspiration therapy, endoscopic sleeve gastroplasty, and intragastric balloon solutions. Aspiration therapy, exemplified by systems like the AspireAssist platform, prioritizes durable drainage interfaces and patient-managed protocols that require different training and follow-up compared with operator-delivered procedures. Endoscopic sleeve gastroplasty divides into stapling systems and suturing systems, each introducing divergent device ergonomics, capital requirements, and clinical learning curves that influence adoption by gastroenterologists and bariatric teams. Intragastric balloons further bifurcate into long-term and short-term balloons; long-term devices emphasize sustained occupancy and retrievable designs while short-term balloons focus on temporary volume displacement with lower procedural complexity.
When viewed through the product-type lens, the market differentiates between reusable balloons and single-use balloons, a distinction that drives procurement preferences, sterilization workflows, and per-procedure cost calculus for facilities. Reusable platforms necessitate validated reprocessing capabilities and capital amortization, whereas single-use options sidestep reprocessing but require consistent supply reliability. From the end-user perspective, the procedure landscape spans ambulatory surgical centers, clinics, hospitals, and dedicated weight loss centers. Ambulatory surgical centers comprise freestanding sites and hospital-affiliated centers, clinics include bariatric and gastroenterology clinics, hospitals range from academic medical centers to community hospitals, and weight loss centers encompass multidisciplinary hubs and single-practice facilities. Finally, procedure setting segmentation into inpatient and outpatient care pathways shapes resource allocation, perioperative protocols, and patient throughput models.
Taken together, these segmentation dimensions inform product development priorities, clinical training programs, and commercialization strategies tailored to the operational realities of different provider types and procedure environments.
Regional dynamics substantially influence how endoscopic weight loss therapies are introduced, reimbursed, and scaled across healthcare systems. In the Americas, established clinical networks and a relatively high prevalence of obesity have created fertile ground for early adoption, accompanied by growing payer interest in cost-effective, minimally invasive options. Providers in this region increasingly pilot outpatient programs and integrate devices into multidisciplinary weight management pathways, thereby accelerating clinician familiarity and patient referral flows.
Europe, Middle East & Africa display heterogeneous adoption patterns rooted in national reimbursement frameworks, variable procedural capacity, and differing regulatory timelines. Western European countries with clear reimbursement pathways tend to lead in technology uptake, while emerging markets within the region explore targeted deployment that aligns with local infrastructural capacities and specialist availability. The Middle East has shown interest in concentrated center-based programs, and parts of Africa focus on pilot initiatives tied to specialized centers.
In Asia-Pacific, rapid urbanization, expanding private healthcare sectors, and high unmet clinical need are driving interest in scalable endoscopic interventions. However, adoption varies with regulatory maturity and the availability of trained endoscopists. Cross-regionally, manufacturers must adapt market entry strategies to local payer structures and procedural workflows, and they must invest in clinician training and post-market evidence generation appropriate for each regulatory and reimbursement environment.
Competitive and collaborative forces define the company landscape supporting endoscopic weight loss therapy. Leading device developers concentrate on enhancing procedural safety, simplifying user interfaces, and broadening the evidence base through investigator-initiated studies and registries. At the same time, strategic partnerships between device suppliers and clinical networks have accelerated training programs, expanded access to early adopter sites, and enabled pragmatic data collection to inform payer conversations. Mergers and acquisitions remain a viable pathway for larger firms to acquire differentiated technologies and to build comprehensive portfolios that span consumables, capital equipment, and digital patient engagement tools.
Investors and corporate development teams evaluate companies based on technological differentiation, intellectual property protection, and the ability to execute robust post-market clinical programs. Meanwhile, smaller innovators often pursue niche strategies that target specific clinical indications or ergonomic improvements to win share within specialist practices. Importantly, supply chain reliability and regulatory compliance have become core competitive factors as providers demand predictable consumable availability and clear evidence of device lifecycle management. Overall, market participants that align clinical evidence generation with pragmatic commercialization and supply strategies position themselves favorably for sustained penetration across multiple care settings.
Industry leaders should adopt a coordinated strategy that aligns clinical evidence generation, payer engagement, and operational deployment to accelerate responsible adoption of endoscopic weight loss therapies. First, prioritize prospective real-world studies and multicenter registries that capture durable patient outcomes and cost-of-care metrics, because robust outcome data materially strengthen reimbursement discussions and clinician confidence. Second, invest in scalable clinician training programs that combine hands-on simulation, proctoring, and digital upskilling to reduce variability in procedural performance and to shorten adoption curves across diverse practice settings.
Concurrently, optimize supply chain resilience by qualifying multiple component sources, exploring regional manufacturing partnerships, and planning inventory buffers that reduce exposure to trade-related disruptions. Firms should also design flexible pricing and service models that consider differences between reusable and single-use products, as well as the distinct procurement priorities of ambulatory surgical centers versus hospitals. Finally, engage payers early with value dossiers that clearly articulate patient selection criteria, downstream cost implications, and real-world outcomes. By synchronizing evidence, training, supply operations, and payer narratives, organizations can create sustainable pathways to scale while maintaining high standards of patient safety and clinical effectiveness.
The research methodology combines primary qualitative insight with systematic secondary analysis to ensure comprehensive, validated conclusions. Primary research involved structured interviews with clinicians, hospital procurement leaders, ambulatory surgery administrators, and device executives, supplemented by advisory board discussions with multidisciplinary specialists. These engagements provided context on procedure workflows, training needs, reimbursement conversations, and procurement decision criteria. Interviews were conducted across varied geographies and provider types to capture diverse operational perspectives.
Secondary research encompassed regulatory documents, peer-reviewed clinical literature, device instructions for use, and policy publications. Data triangulation occurred by cross-referencing interview inputs with published evidence and regulatory guidance to reduce bias and to validate emerging themes. Analytical techniques included thematic coding of qualitative inputs, comparative assessment of device features and procedural workflows, and scenario analysis for supply chain and policy impacts. The methodology also accounted for limitations, including variability in regional reimbursement landscapes and the evolving nature of long-term clinical outcome data. Ethical considerations and confidentiality agreements governed all primary interviews and data handling to protect participant anonymity and proprietary information.
In conclusion, endoscopic weight loss therapy stands at a pivotal juncture shaped by technological refinement, evidence maturation, and changing care delivery economics. The cumulative effect of improved device ergonomics, pragmatic outcome studies, and expanded training infrastructures has increased the feasibility of broadening procedural access beyond specialized tertiary centers. Yet, the pathway to routine clinical integration hinges on coordinated action across evidence generation, payer engagement, and supply chain resilience.
Looking ahead, stakeholders who proactively align clinical development with reimbursement strategies and who invest in scalable training and post-procedure care models will most effectively translate innovation into routine practice. Trade policy shifts and regional heterogeneity in reimbursement require adaptive commercialization plans and localized value propositions. Ultimately, the successful diffusion of endoscopic obesity interventions will depend on demonstrable patient benefit, clear economic rationale for payers, and operational models that deliver reliable, high-quality care across diverse clinical settings.